Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Pediatric Hodgkin disease in North Tunisia: Clinical and therapeutic study
Cancer/Radiotherapie, Volume 16, No. 7, Year 2012
Notification
URL copied to clipboard!
Description
Purpose: To assess the epidemiological, clinical and therapeutic aspects of pediatric Hodgkin disease (HD) and to study prognosis factors. Patients and methods: We retrospectively reviewed the medical records of children (≤ 18 years) with HD treated between 1st January 1994 and 31st December 2004. Chemotherapy was undertaken in different departments of hematology and oncology in the North of the country and radiotherapy was centralized at the Salah-Azaïz National Cancer Institute. Results: One hundred fourteen consecutively treated patients were collected. Median age was 12 years (4-18 years) and sex-ratio was 2.25. Peripheral lymphadenopathy was the predominant circumstance of HD detection (82.5%). The predominant histologic type was nodular sclerosing (56%). Treatment included chemotherapy and involved-field radiotherapy. With a mean follow-up of 23.5 months, relapse rate was 12.2%. Five-year overall survival (OS) and event-free survival (EFS) rates were 95% and 76%, respectively. Five-year OS was 98.2% and 90.8% for early and advanced stages respectively. In multivariate analysis, stage IV (P= 0.029) and early response to initial treatment (P= 0.003) retained statistical significance for EFS whereas the only prognostic factor for OS was stage IV (P= 0.002). The long-term side effects were rare. No secondary tumor was noted. Conclusion: Combined-modality therapy using chemotherapy and involved-field radiotherapy was effective and well-tolerated in early stage pediatric HD. Stage IV patients should be referred to specialized units for intensive treatment. The short median follow-up in our study cannot allow considering long-term effects. © 2012.
Authors & Co-Authors
Kochbati, Lotfi
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Fdhila, Faten
Tunisia, Tunis
Université de Tunis el Manar, Hôpital D'enfants Béchir Hamza de Tunis
Belaid, Imtinene
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Rifi, Hela
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Barsaoui, Siheme
Tunisia, Tunis
Université de Tunis el Manar, Hôpital D'enfants Béchir Hamza de Tunis
Ben Romdhane, Neila Kédidi
Tunisia, Tunis
Hôpital la Rabta
Bel Hadj Ali, Z.
Tunisia, Tunis
Université de Tunis el Manar, Hôpital Aziza Othmana
Mézlini, Amel
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Oubich, Fayçal
Tunisia, Tunis
Université de Tunis el Manar, Hôpital D'enfants Béchir Hamza de Tunis
Maâlej, Mongi
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Statistics
Citations: 10
Authors: 10
Affiliations: 4
Identifiers
Doi:
10.1016/j.canrad.2012.09.002
ISSN:
12783218
e-ISSN:
17696658
Research Areas
Cancer
Maternal And Child Health
Study Design
Cohort Study
Study Locations
Tunisia